<DOC>
	<DOCNO>NCT00104299</DOCNO>
	<brief_summary>Antineutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis common type small blood vessel inflammation adult . ANCA-associated vasculitis include Wegener 's granulomatosis ( WG ) microscopic polyangiitis ( MPA ) . Rituximab man-made antibody use treat certain type cancer . The purpose study determine effectiveness rituximab treat patient WG MPA . Study hypothesis : Rituximab inferior conventional therapy ability induce disease remission Month 6 .</brief_summary>
	<brief_title>Rituximab Treatment Wegener 's Granulomatosis Microscopic Polyangiitis</brief_title>
	<detailed_description>Current conventional therapy ANCA-associated vasculitis ( AAV ) associate high incidence treatment failure , disease relapse , substantial toxicity , patient morbidity mortality . Rituximab monoclonal antibody use treat non-Hodgkin 's lymphoma . This study evaluate efficacy rituximab glucocorticoid induce disease remission patient severe form AAV ( WG MPA ) . The study consist two phase : 6-month remission induction phase , follow 12-month remission maintenance phase . All participant receive least 1 g pulse intravenous methylprednisolone dose-equivalent another glucocorticoid preparation . Depending participant 's condition , may receive 3 day intravenous methylprednisolone total 3 g methylprednisolone ( dose-equivalent ) . During remission induction phase , participant receive oral prednisone daily ( 1 mg/kg/day , exceed 80 mg/day ) . Prednisone taper complete Month 6 study visit . Next , participant randomly assign one two arm . Arm 1 participant receive rituximab ( 375 mg/m^2 ) infusion weekly 4 week cyclophosphamide ( CYC ) placebo daily 3 6 month . Arm 2 participant receive rituximab placebo infusion weekly 4 week CYC daily 3 6 month . During remission maintenance phase , participant Arm 1 discontinue CYC placebo start oral azathioprine ( AZA ) placebo daily Month 18 . Participants Arm 2 discontinue CYC start AZA daily Month 18 . Participants fail treatment Month 6 cross treatment arm unless specific contraindication . Participants either group reach clinical remission complete 6 month therapy may switch CYC/placebo AZA/placebo direct physician . All participant follow least 18 month . Initially , study visit weekly , progress monthly quarterly visit study proceeds . Blood collection occur study visit .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Weight least 88 pound ( 40 kilogram ) Diagnosis Wegener 's granulomatosis microscopic polyangiitis accord definition Chapel Hill Consensus Conference Newly diagnose patient Wegener 's granulomatosis microscopic polyangiitis OR must experience disease flare characterize : ( ) active disease Birmingham Vasculitis Activity Score Wegener 's granulomatosis ( BVAS/WG ) 3 great would normally require treatment CYC ; OR ( b ) disease severe enough require treatment CYC ; OR ( c ) must positive either PR3ANCA ( ANCA direct proteinase 3 ) MPOANCA ( ANCA direct myeloperoxidase ) screen Willing use acceptable form contraception duration study 1 year stop study medication Willing report pregnancy ( female participant male participant ' partner ) occur time study 1 year stop study medication Parent guardian willing provide inform consent , applicable Diagnosis ChurgStrauss Syndrome accord definition Chapel Hill Consensus Conference Have limit disease would normally treat CYC Requires mechanical ventilation alveolar hemorrhage History severe allergic reaction human chimeric monoclonal antibody Active systemic infection Have deepspace infection , osteomyelitis , septic arthritis , pneumonia complicate pleural cavity lung abscess , within 6 month prior study entry History current hepatitis B C infection HIV ( human immunodeficiency virus ) infect Acute chronic liver disease , opinion investigator , may interfere study History active cancer diagnose within last 5 year . Individuals squamous cell basal cell carcinoma skin individual cervical carcinoma situ receive curative surgical treatment may eligible study . History antiglomerular basement membrane ( antiGBM ) disease Other uncontrolled disease , include drug alcohol abuse , may interfere study Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ANCA</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Wegener 's Granulomatosis</keyword>
	<keyword>microscopic polyangiitis</keyword>
	<keyword>ANCA-positive</keyword>
	<keyword>ANCA-associated</keyword>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>MPA</keyword>
</DOC>